BARCELONA, MAY 22 2017 – Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announces it has closed a Series A financing of 15 million Euro. The leading investors include new investors Ysios Capital (Barcelona, Spain), Omega Funds (Boston, MA, USA), Banco Sabadell (Spain) as well as current investor Innogest Capital (Milan, Italy).

In conjunction with the financing, Josep L. Sanfeliu, General Partner at Ysios Capital, and Claudio Nessi, Managing Director at Omega Funds will join Anaconda Biomed’s Board of Directors. Giovanni Leo, will continue to represent Innogest Capital in Anaconda Biomed’s Board of Directors.

«This financing provides Anaconda Biomed the capital necessary to substantially progress the development of our ANCD BRAIN™ device, including the validation and verification process, clinical studies to support the initial commercialization of ANCD BRAIN™ in Europe and an initial submission to FDA», said Ofir Arad, Co-Founder and  CEO of Anaconda Biomed. «Furthermore, the addition of Josep L. and Claudio to our Board will strengthen the extensive operational and financial expertise available to our management team».

«The investment in Anaconda Biomed is great news not only for the consolidation of the medtech ecosystem in Spain and Barcelona, but also for the amazing work of the founders in putting together a disruptive medical device by combining excellent medicine with high tech chemistry», said Josep L. Sanfeliu partner at Ysios Capital.

«We are very pleased for this sizable investment round following our first seed investment in Anaconda Biomed’s one year ago», said Claudio Rumazza, Partner at Innogest Capital. «With its innovative design addressing a clear clinical need and a capable management team, Anaconda Biomed is well positioned to be a winner in the high growth stroke treatment market and a success story for European medtech industry».

«Mechanical thrombectomy is quickly becoming a game changing procedure for ischemic stroke patients», said Claudio Nessi, partner at Omega Funds. «Our analysis suggests that Anaconda Biomed’s innovative device may become the next generation device and therefore a market leader».

Additional investors include Banco Sabadell (Spain) and other investors.

Stroke is the fifth leading cause of death in the U.S. and a leading cause of disability, according to the American Heart Association/American Stroke Association (AHA/ASA). Additionally, every 2 seconds someone in the world is undergoing a stroke. Every 10 seconds someone in the world dies from a stroke. In the USA alone, there are about 690,000 annual incidences of AIS.

About Anaconda Biomed
Anaconda Biomed, headquartered in Barcelona, Spain, is among the world’s most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS). Learn more at: www.anaconda.bio

About Ysios Capital
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital currently has close to €200M ($220M) in assets under management. Ysios BioFund II Innvierte was closed in September 2016 at €126.4M.  For more information, please visit: www.ysioscapital.com

About Innogest Capital
Innogest Capital is a venture capital firm with offices in Milan, Turin and San Francisco that focuses on promising early stage healthcare ventures developing medical devices, diagnostics and digital health. With over €200 million of capital under management Innogest Capital is particularly active in cardiology, neurology and oncology. Learn more at: www.innogestcapital.com

About Omega Funds
Omega Funds is a leading venture capital and growth equity investor within the broad life sciences sector. Founded in 2004, the firm is based in Boston and has a strategic relationship with NeoMed Management, a Jersey headquartered investment firm, which broadens its capabilities in Europe. For further information, please visit: www.omegafunds.net

Forward-Looking Statements. This press release contains statements that are “forward-looking statements” based upon management’s current expectations and assumptions and are subject to many risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.

Media Contact

Anaconda Biomed – Uri Figil
Tel: +34 936 397 710
Email: info@anaconda.bio